Inaugural Legends of Science Oncology Symposium Friday, September 12, 2025 |
Through this day of scientific talks and panel discussions on the future of cancer research, discover how UC San Diego researchers and industry trailblazers are revolutionizing cancer care through breakthrough therapeutics, innovative research, and AI-driven advancements in oncology to transform treatment and reshape the scientific landscape.
The symposium will conclude with the Legends Cocktail Party and Networking Reception, which will provide a unique environment to discover and connect with top researchers, academic leaders, industry experts, visionary venture capitalists, and legendary surfers.
The symposium is free for Moores Members and Trainees. Register today! RSVP | Download the Agenda>>
|
Catheryn Yashar, MD, FASTRO Named ASTRO President-Elect |
Moores Member Dr. Catheryn Yashar has been named president-Elect of the American Society for Radiation Oncology (ASTRO). In her research and practice, Dr. Yashar advances priorities that include advocating for reimbursement models that accurately reflect both the cost and clinical value of radiation oncology, fostering stronger collaborations across related medical specialties, and enhancing the visibility of radiation medicine within the broader medical community. Her leadership emphasizes increasing awareness of radiation therapy’s role in treating non-cancerous conditions, further improving patient care. Learn More>>
|
36th Annual Usha Mahajani Symposium on Molecular Medicine: 3D Modeling of Tumor Biology |
This year’s symposium will take place on September 5, 2025 at the Conrad T. Prebys Auditorium at the Salk Institute for Biological Sciences, enabling scientists in industry and academia to network and apprise leading-edge research in the field. Learn More>>
|
Leslie Crews, PhD Awarded American Society of Hematology (ASH) Bridge Grant |
Moores Member Dr. Leslie Crews received this ASH grant for her project, “Core Molecular Regulators of Lipid Homeostasis in Hematopoietic Progenitor Cell Aging,” one of only 25 research initiatives selected nationwide for support through this funding mechanism. Kudos to Dr. Crews! Learn More>>
|
|
|
FDA-AACR Workshop: Approach to Novel Oncology Endpoint Development
|
Hybrid (in person + virtual options)
Thursday, September 11, 2025
8:00 a.m. to 3:30 p.m. EDT
Hilton Alexandria Old Town
Alexandria, Virginia
|
- Overall survival remains a key measure, yet it often is impractical as a primary endpoint in early-stage or rare cancer trials.
- Novel endpoints such as pCR and MRD offer promise, yet they must be validated rigorously to ensure that they reflect long-term benefit and do not compromise patient outcomes.
|
As such, this workshop will explore successful strategies, unmet needs, and evidence requirements to support novel endpoints in regulatory decision-making. Register>>
|
|
|
Registration Open: Compassionate Communication Workshop |
This free, skills-based workshop is for healthcare professionals, medical educators, and researchers. Through interactive sessions, participants will learn how to communicate with greater compassion—and, in turn, greater effectiveness—with patients, health care teams, and medical trainees. Learn More and Register>>
|
|
|
FEATURED FUNDING OPPORTUNITIES
|
LIMITED SUBMISSION (UCSD FACULTY ONLY) |
Application Deadline: September 18, 2025
|
Budget: $30,000 for 6 months
|
Application Deadline: November 21, 2025
|
Budget: $375,000 for 3 years
|
|
|
| mAChR4 suppresses liver disease via GAP-induced antimicrobial immunity
|
Bernd Schnabl, MD (Cancer Biology and Signaling) and Michael Karin, PhD (Solid Tumor Therapeutics)
|
|
|
| Therapy for stage IV non-small cell lung cancer without driver alterations: ASCO living guideline, version 2025.1 |
Journal of Clinical Oncology
|
Lyudmila Bazhenova, MD (Solid Tumor Therapeutics)
|
|
|
| Noncanonical roles of chemokine regions in CCR9 activation revealed by structural modeling and mutational mapping |
Irina Kufareva, PhD (Cancer Biology and Signaling) and Thomas Handel, PhD (Solid Tumor Therapeutics)
|
|
|
CLINICAL TRIALS OFFICE (CTO)
|
9MW2821-2022-CP103: An Open-Label, Multicenter, Phase Ib Dose Randomization Study of Bulumtatug Furvedotin (BFv; 9MW2821) in Subjects with Recurrent or Metastatic Triple-Negative Breast Cancer Previously Treated with Antibody-Drug Conjugates
PI: Rebecca Shatsky, MD
NCT: NCT06908928
KO-MEN-015: A Phase Ia/Ib Study of the Safety, Pharmacokinetics, and Antitumor Activity of the Oral Menin Inhibitor Ziftomenib in Combination with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors (GIST) After Imatinib Failure
PI: Jason Sicklick, MD, FACS
NCT: NCT06655246
|
EAY191-S3: Phase II Study of Paclitaxel (NSC 673089) Ipatasertib (NSC 781451) in Taxane-Refractory Participants with PTEN/AKT-Altered Advanced Non-Breast Solid Tumors: A Combo-MATCH Treatment Trial
PI: Shumei Kato, MD
NCT: NCT05554380
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT (COE)
|
Training Native Cancer Navigators at Moores |
On August 21, 2025, COE partnered with the Indian Health Service and UC Davis to host a day of training in Comer Commons for a new cohort of external cancer navigators from tribal and urban programs across Southern California. Eight new navigators received a tour of Moores and were given an overview of the patient experience and support services offered at Moores. The training fostered a discussion on how to better support the needs of Native patients and how future bidirectional learning opportunities can be supported.
|
|
|
|
